Literature DB >> 23777636

Clinical neurotransplantation protocol for Huntington's and Parkinson's disease.

William Omar Contreras Lopez1, Guido Nikkhah, Ulf D Kahlert, Donata Maciaczyk, Tomasz Bogiel, Sven Moellers, Elisabeth Schültke, Máté Döbrössy, Jaroslaw Maciaczyk.   

Abstract

PURPOSE: The concept of transplantation of neuronal cells to treat Huntington's and Parkinson's diseases is based on the proven principle that dopaminergic and GABA-ergic progenitor neurons (from the human developing ventral mesencephalon and whole ganglionic eminence) can survive, differentiate and functionally integrate into an allogenic host brain. However, several donor and host-specific variables play a major role in the safety and outcome of this procedure. In this paper, we seek to summarize an updated neural transplantation protocol, based on our institutional experience and many years of collaboration with other neurotransplantation centers.
METHODS: We present a detailed clinical neurotransplantation protocol for Parkinson's (PD) and Huntington's (HD) diseases with special emphasis in understanding the anatomical relationships of the human fetal tissue that are relevant for selection of the desired cell populations.
RESULTS: Two detailed step-wise neurotransplantation protocols are presented, outlining strategies facilitating the avoidance of possible procedure-related complications.
CONCLUSIONS: In this paper we delineated some crucial technical factors enabling the execution of a safe and effective neural transplantation. The protocols presented here might contribute to further development of the experimental clinical neurotransplantation towards a routine therapeutic procedure.

Entities:  

Mesh:

Year:  2013        PMID: 23777636     DOI: 10.3233/RNN-130317

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  6 in total

1.  Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.

Authors:  Ulf D Kahlert; Menglin Cheng; Katharina Koch; Luigi Marchionni; Xing Fan; Eric H Raabe; Jarek Maciaczyk; Kristine Glunde; Charles G Eberhart
Journal:  Int J Cancer       Date:  2015-10-13       Impact factor: 7.396

2.  ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres.

Authors:  Ulf D Kahlert; Abigail K Suwala; Eric H Raabe; Florian A Siebzehnrubl; Maria J Suarez; Brent A Orr; Eli E Bar; Jaroslaw Maciaczyk; Charles G Eberhart
Journal:  Brain Pathol       Date:  2015-02-08       Impact factor: 6.508

Review 3.  [Huntington's disease].

Authors:  J D Rollnik
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

4.  DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.

Authors:  Allison R Hanaford; Tenley C Archer; Antoinette Price; Ulf D Kahlert; Jarek Maciaczyk; Guido Nikkhah; Jong Wook Kim; Tobias Ehrenberger; Paul A Clemons; Vlado Dančík; Brinton Seashore-Ludlow; Vasanthi Viswanathan; Michelle L Stewart; Matthew G Rees; Alykhan Shamji; Stuart Schreiber; Ernest Fraenkel; Scott L Pomeroy; Jill P Mesirov; Pablo Tamayo; Charles G Eberhart; Eric H Raabe
Journal:  Clin Cancer Res       Date:  2016-03-24       Impact factor: 12.531

5.  Ultrastructural Immunocytochemistry of GABAergic Cells in Neocortical Neurotransplants.

Authors:  Z N Zhuravleva; S S Khutsyan; G I Zhuravlev
Journal:  Bull Exp Biol Med       Date:  2022-09-05       Impact factor: 0.737

6.  Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.

Authors:  Jing-Wei Zhao; Sean C Dyson; Christina Kriegel; Pam Tyers; Xiaoling He; Tarek M Fahmy; Su M Metcalfe; Roger A Barker
Journal:  Dis Model Mech       Date:  2014-08-01       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.